|Audit||Nominating and Governance||Compensation & Mgmt Development||Mergers and Acquisitions|
|Rolf A. Classon|
Chairman, Hill-Rom Holdings, Inc.
Mr. Classon became Chairman of the Board of Hill-Rom in 2006. He served as Interim President and Chief Executive Officer of Hill-Rom from May 2005 until March 2006 and as Vice Chairman of the Board from December 2003 until his election as Interim President and Chief Executive Officer. From 2002 to 2004, Mr. Classon served as Chairman of the Executive Committee of Bayer Healthcare AG, the healthcare division of Bayer AG, a global healthcare and chemicals company, and, from 1995 to 2002, Mr. Classon served as President of Bayer Diagnostics. From 1991 to 1995, Mr. Classon was an Executive Vice President in charge of Bayer Diagnostics’ Worldwide Marketing, Sales and Service operations. From 1990 to 1991, Mr. Classon was President and Chief Operating Officer of Pharmacia Biosystems A.B. Prior to 1990, Mr. Classon served as President of Pharmacia Development Company Inc. and Pharmacia A.B.’s Hospital Products Division. Mr. Classon currently serves as a director of Fresenius Medical Care, Tecan Group, Catalent, Inc.and Perrigo Company plc, and was previously a director of Auxilium Pharmaceuticals, Inc., through January 2015, Millipore Corporation until 2010, and PharmaNet Development Group, Inc. until 2009.
Mr. Classon has extensive experience in the health care industry, including positions in management and on the boards of several companies. His service as a senior officer in numerous international corporations brings an extensive breadth of knowledge and valuable insight to the Board.
|John J. Greisch|
|William G. Dempsey|
|Gary L. Ellis|
|Stacy Enxing Seng|
|James R. Giertz|
|Charles E. Golden|
|William H. (Hank) Kucheman|
|Ronald A. Malone|
|Nancy M. Schlichting|
Meetings and Committees of the Board of Directors
It is the general policy of the Company that all significant decisions be considered by the Board as a whole. As a consequence, the committee structure of the Board is limited to those committees considered to be basic to, or required for, the operation of a publicly owned company. Currently these committees are the Compensation and Management Development Committee, Audit Committee and Nominating/Corporate Governance Committee, each of which has a written charter adopted by the Board of Directors. The Nominating/Corporate Governance Committee recommends the members and chairs of these committees to the Board. The Audit Committee, Compensation and Management Development Committee and Nominating/Corporate Governance Committee are made up of only independent directors. The current charter for each of the Board's standing committees is available on this website and is available in print from this website or to any shareholder who requests it through the Company's Investor Relations office.
During the fiscal year ended September 30, 2009, the Board of Directors of the Company held seven meetings. During this period, no member of the Board of Directors attended fewer than 75% of the aggregate of the number of meetings of the full Board of Directors and the number of meetings of the committees on which he or she served.